J INTERN MED:较高针对apoB100 p210的自身抗体水平与女性较低的房颤发生率相关

2021-09-18 MedSci原创 MedSci原创

心房颤动(AF)与全身和心房组织炎症相关。这些结果支持自身体液免疫与房颤之间的关联。

心房颤动(AF)与全身和心房组织炎症相关。AF患者氧化LDL水平增加,并被认为是导致炎症的重要分子之一。针对氧化型LDL和载脂蛋白B100(LDL的蛋白质成分)的自身抗体与动脉粥样硬化疾病相关。然而,这些自身抗体是否与AF的发生相关尚未明确。

近日,内科学领域权威杂志Journal of Internal Medicine上发表一篇研究文章,研究人员在一个基于人群的大型队列中探究了针对氧化载脂蛋白B100肽自身抗体和AF发生率之间的相关性。

研究人员通过ELISA测量了来自马尔默饮食和癌症队列中5169名参与者血浆中针对天然和醛修饰的apoB100肽210(p210)和45的IgM和IgG水平。

在21.3年的随访期间,研究人员共记录了769起AF事件。基线时针对天然p210的IgM水平较高的个体患AF的风险较低,但在调整年龄和性别后,这种关联并未持续。女性针对天然p210的IgM水平高于男性(0.70±0.22 AU vs. 0.63±0.21 AU,p<0.001)。IgM与天然p210和AF之间的关联在性别之间存在显著差异(交互作用的p=0.024),在调整风险因素和合并症后,具有较高针对p210 IgM水平的女性发生AF的风险较低(第4与第1个四分位数风险比[95%置信区间]为0.67[0.49-0.91];p=0.01)。

由此可见,这些结果支持自身体液免疫与房颤之间的关联。

原始出处:

Kari Anne Sveen.et al.High levels of autoantibodies against apoB100 p210 are associated with lower incidence of atrial fibrillation in women.J INTERN MED.2021.https://doi.org/10.1111/joim.13393

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826728, encodeId=71ed1826e28f3, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 27 04:46:38 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033923, encodeId=94b8203392368, content=<a href='/topic/show?id=1418265edc' target=_blank style='color:#2F92EE;'>#ApoB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2657, encryptionId=1418265edc, topicName=ApoB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Fri Sep 24 00:46:38 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786034, encodeId=238c1e8603486, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Wed Oct 06 18:46:38 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056075, encodeId=433110560e5ca, content=这有点难理解。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Wed Sep 29 13:10:57 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611257, encodeId=c158161125e7a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Sep 20 10:46:38 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052941, encodeId=58cb1052941d5, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sun Sep 19 03:04:10 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052916, encodeId=18e2105291652, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Sep 18 23:14:25 CST 2021, time=2021-09-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1826728, encodeId=71ed1826e28f3, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 27 04:46:38 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033923, encodeId=94b8203392368, content=<a href='/topic/show?id=1418265edc' target=_blank style='color:#2F92EE;'>#ApoB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2657, encryptionId=1418265edc, topicName=ApoB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Fri Sep 24 00:46:38 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786034, encodeId=238c1e8603486, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Wed Oct 06 18:46:38 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056075, encodeId=433110560e5ca, content=这有点难理解。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Wed Sep 29 13:10:57 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611257, encodeId=c158161125e7a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Sep 20 10:46:38 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052941, encodeId=58cb1052941d5, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sun Sep 19 03:04:10 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052916, encodeId=18e2105291652, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Sep 18 23:14:25 CST 2021, time=2021-09-18, status=1, ipAttribution=)]
    2021-09-24 axin009
  3. [GetPortalCommentsPageByObjectIdResponse(id=1826728, encodeId=71ed1826e28f3, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 27 04:46:38 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033923, encodeId=94b8203392368, content=<a href='/topic/show?id=1418265edc' target=_blank style='color:#2F92EE;'>#ApoB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2657, encryptionId=1418265edc, topicName=ApoB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Fri Sep 24 00:46:38 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786034, encodeId=238c1e8603486, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Wed Oct 06 18:46:38 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056075, encodeId=433110560e5ca, content=这有点难理解。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Wed Sep 29 13:10:57 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611257, encodeId=c158161125e7a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Sep 20 10:46:38 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052941, encodeId=58cb1052941d5, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sun Sep 19 03:04:10 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052916, encodeId=18e2105291652, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Sep 18 23:14:25 CST 2021, time=2021-09-18, status=1, ipAttribution=)]
    2021-10-06 tulenzi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1826728, encodeId=71ed1826e28f3, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 27 04:46:38 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033923, encodeId=94b8203392368, content=<a href='/topic/show?id=1418265edc' target=_blank style='color:#2F92EE;'>#ApoB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2657, encryptionId=1418265edc, topicName=ApoB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Fri Sep 24 00:46:38 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786034, encodeId=238c1e8603486, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Wed Oct 06 18:46:38 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056075, encodeId=433110560e5ca, content=这有点难理解。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Wed Sep 29 13:10:57 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611257, encodeId=c158161125e7a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Sep 20 10:46:38 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052941, encodeId=58cb1052941d5, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sun Sep 19 03:04:10 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052916, encodeId=18e2105291652, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Sep 18 23:14:25 CST 2021, time=2021-09-18, status=1, ipAttribution=)]
    2021-09-29 13f0c37dm61暂无昵称

    这有点难理解。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1826728, encodeId=71ed1826e28f3, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 27 04:46:38 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033923, encodeId=94b8203392368, content=<a href='/topic/show?id=1418265edc' target=_blank style='color:#2F92EE;'>#ApoB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2657, encryptionId=1418265edc, topicName=ApoB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Fri Sep 24 00:46:38 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786034, encodeId=238c1e8603486, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Wed Oct 06 18:46:38 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056075, encodeId=433110560e5ca, content=这有点难理解。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Wed Sep 29 13:10:57 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611257, encodeId=c158161125e7a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Sep 20 10:46:38 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052941, encodeId=58cb1052941d5, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sun Sep 19 03:04:10 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052916, encodeId=18e2105291652, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Sep 18 23:14:25 CST 2021, time=2021-09-18, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1826728, encodeId=71ed1826e28f3, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 27 04:46:38 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033923, encodeId=94b8203392368, content=<a href='/topic/show?id=1418265edc' target=_blank style='color:#2F92EE;'>#ApoB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2657, encryptionId=1418265edc, topicName=ApoB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Fri Sep 24 00:46:38 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786034, encodeId=238c1e8603486, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Wed Oct 06 18:46:38 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056075, encodeId=433110560e5ca, content=这有点难理解。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Wed Sep 29 13:10:57 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611257, encodeId=c158161125e7a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Sep 20 10:46:38 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052941, encodeId=58cb1052941d5, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sun Sep 19 03:04:10 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052916, encodeId=18e2105291652, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Sep 18 23:14:25 CST 2021, time=2021-09-18, status=1, ipAttribution=)]
    2021-09-19 学医无涯

    学习一下

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1826728, encodeId=71ed1826e28f3, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 27 04:46:38 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2033923, encodeId=94b8203392368, content=<a href='/topic/show?id=1418265edc' target=_blank style='color:#2F92EE;'>#ApoB#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2657, encryptionId=1418265edc, topicName=ApoB)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad8182, createdName=axin009, createdTime=Fri Sep 24 00:46:38 CST 2021, time=2021-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1786034, encodeId=238c1e8603486, content=<a href='/topic/show?id=48f613605c4' target=_blank style='color:#2F92EE;'>#p21#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13605, encryptionId=48f613605c4, topicName=p21)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=54f9127, createdName=tulenzi, createdTime=Wed Oct 06 18:46:38 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056075, encodeId=433110560e5ca, content=这有点难理解。, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Wed Sep 29 13:10:57 CST 2021, time=2021-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611257, encodeId=c158161125e7a, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Sep 20 10:46:38 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052941, encodeId=58cb1052941d5, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Sun Sep 19 03:04:10 CST 2021, time=2021-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1052916, encodeId=18e2105291652, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat Sep 18 23:14:25 CST 2021, time=2021-09-18, status=1, ipAttribution=)]
    2021-09-18 1209e435m98(暂无昵称)

    学习了,谢谢分享

    0

相关资讯

Stroke:华法林和4种直接口服抗凝剂对房颤患者痴呆风险的影响有何不同?

在这个庞大的亚洲房颤人群中,总体上,DOAC具有与华法林相似的痴呆风险。在65至74岁或有卒中病史的人群中,DOAC似乎比华法林更有益。对于特定的DOAC,与华法林相比,只有依度沙班与更低的痴呆风险相

Neurology:房颤、卒中和无症状脑血管疾病的关系

AF与广泛的脑血管病变有关。需要进一步研究以确定是否可以将脑血管MRI标志物添加到当前的治疗指南中,以进一步个性化AF患者的抗凝治疗,并进一步归纳AF与脑血管疾病以及痴呆之间关联的潜在发病机制。

JAHA:自发性脑出血患者房颤情况分析

ICH患者AF患病率和OAC的使用随着时间的推移有所增加。病前使用OAC与ICH后不良结局相关,因此,在AF患者开始或继续OAC治疗之前需要更好地识别ICH风险。

Circulation:早期心律控制治疗给心衰合并房颤的患者带来的临床益处

有心衰体征或症状的患者确诊合并房颤后 1 年内开始心律控制治疗可带来显著的临床益处

Lancet Neurol:当房颤遇上自发性颅内出血,患者还能不能口服抗凝治疗?

当房颤遇上自发性颅内出血,患者还能不能口服抗凝治疗?

ESC 2021丨马长生教授:预期ETNA-AF中国研究结果将与国际一致,艾多沙班在大多数房颤患者中具有优势

ESC 2021大会上多项ETNA-AF研究结果发布,一起来看下我国房颤抗凝的现状吧。